Evaluation of the transplant recipient and donor: Molecular approach to tissue typing, flow cytometry and alternative approaches to distributing organs

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 3, 1997, Pages 299-303

  Takemoto, Steven K ^a   Terasaki, Paul I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; CREATININE; DNA; HLA ANTIBODY; HLA ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ALGORITHM; ARTICLE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA MATCHING; HUMAN; IMMUNE RESPONSE; KIDNEY SIZE; KIDNEY TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; RECIPIENT; TISSUE TYPING;

EID: 0030741960     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199705000-00016     Document Type: Article

References (39)

1. Garovoy MR, Rheinschmidt MA, Bigos M, Perkins H, Colomb B, Feduska N, Salvatierra O: Flow cytometry analysis: a high technology crossmatch technique facilitating transplantation. Transplant Proc 1983, 15:1939-1944.
2. Cook DJ, Terasaki PI, Iwaki Y, Terashita G, Lau M: An approach to reducing early kidney transplant failure by flow cytometry crossmatching. Clin Transplant 1987, 1:253-256.
3. Ogura K, Terasaki PI, Johnson C, Mendez R, Rosenthal JT, Ettenger R, Martin DC, Dainko E, Cohen L, Mackett T et al.: The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 1993, 56:294-298.
4. Mahoney RJ, Norman DJ, Colombe BW, Garovoy MR, Leeber DA: Identification of high- and low-risk second kidney grafts. Transplantation 1996, 61:1349-1355. In a study including 103 second graft recipients, those whose first graft functioned for at least 3 months had 78% 3-year survival regardless of flow crossmatch result. Those with previous graft failure within 3 months had 84% 3-year survival with a negative flow crossmatch and 44% survival with a positive crossmatch.
5. Takemoto S: Sensitization and crossmatch. In Clinical Transplants 1995. Edited by Cecka JM, Terasaki PI. Los Angeles: UCLA Tissue Typing Laboratory; 1996:417-432. Patients with no HLA antibody had 82% 1-year survival regardless of induction therapy. Patients with PRA > 50% had 78% 1-year survival with induction therapy (n=2800) and 72% 1-year survival without (n=4500, P < 0.001). Patients with PRA > 50% and zero residues mismatched had 72% 3-year survival compared with 62% for patients with residues mismatched.
6. Cicciarelli J, Helstab K, Mendez R: Flow cytometry PRA, a new test that is highly correlated with graft survival. Clin Transplantation 1992, 6:159-164.
7. Shroyer TW, Deierhoi MH, Mink CA, Cagle LR, Hudson SL, Rhea SD, Diethelm AG: A rapid flow cytometry assay for HLA antibody detection using a pooled cell panel covering 14 serological crossreacting groups. Transplantation 1995, 59:626-630. Flow cytometry detected HLA antibodies in 22% of samples testing negative by cytotoxicity.
8. Sumitran-Karuppan S, Moller E: The use of magnetic beads coated with soluble HLA class I or class II proteins in antibody screening and for specificity determination of donor-reactive antibodies. Transplantation 1996, 61:1539-1545. A method for using magnetic beads coated with soluble HLA antigens for detecting specific HLA antibodies was described. Of 50 transplant recipients tested, 20 had detectable donor-specific HLA antibodies using this method; seven of these patients lost their graft, six had early acute rejection and seven had functioning grafts (P < 0.001).
9. Lederer SR, Schneeberger H, Albert E, Johnson JP, Gruber R, Land W, Burkhardt K, Hillebrand G, Feincht HE: Early renal graft dysfunction. Transplantation 1996, 61:313-319. Pretransplant serum samples from patients with early dysfunction had HLA class II antibodies detectable by flow cytometry in 44 out of 86 cases. Cytotoxic antibodies were detectable in only 20 of these samples.
10. Puig N, Pallardo LM, Carpio N, Sanchez P, Planelles D, Marin C, Mortoro JA: Monocyte cross-match in renal transplantation. Transplant Proc 1995, 27:2412. Donor-specific monocyte crossmatch by flow cytometry was positive for 18 out of 76 patients. Only one case was positive exclusively with monocytes. No difference in 1-year graft survival for a positive crossmatch was detected.
11. Kao KJ, Scornik JC, Small SJ: Enzyme-linked immunoassay for anti-HLA antibodies: an alternative to panel studies by lymphocytoxicity. Transplantation 1993, 55:192-196.
12. Buelow R, Mercier I, Glanville L, Regan J, Ellingson L, Janda G, Claas F, Colombe B, Gelder F, Gross-Wilde H et al.: Detection of panel-reactive anti-HLA class I antibodies by enzyme-linked immunosorbent assay or lymphocytotoxicity. Hum Immunol 1995, 44:1-11. A multicenter study resulted in r values ranging from 0.89 to 0.96 using PRA-STAT compared with 0.57 to 0.94 for PRA tested using cytotoxicity.
13. Zachary AA, Griffin J, Lucas DP, Hart JM, Leffel MS: Evaluation of HLA antibodies with the PRA-STAT test. Transplantation 1995, 60:1600-1606. High correlation was noted between cytotoxicity and PRA-STAT (r=0.78). Of 66 sera reactive in both assays, 18% had identical specificities, and 47% had different specificities. Of particular concern was reactivity by PRA-STAT to serum normally used as negative control reagents in cytotoxicity assays.
14. Bryan CF, Baier KA, Flora-Ginter G, Shield CF, Warady BA, Aeder MI, Borkon AM, Estep TH, Forster J, Landreneau MD et al.: Detection of HLA IgG antibodies by two enzyme-linked immunoassays, solubilized HLA class I and PRA-STAT. Transplantation 1995, 60:1588-1594. Pooled platelet ELISA PRA technique [11] had a higher correlation (r=0.77) to cytotoxicity than PRA-STAT (r=0.42), PRA-STAT was unable to confirm the specificities for 13 out of 29 routinely used HLA class-I typing sera.
15. Fuller TC, Fuller A, McCormack JM, Rodey GE: In support of the findings of Bryan et al. [Letter]. Transplantation 1996, 61:1127-1128. PRA-STAT was unable to confirm the specificities for 19 out of 27 routinely used HLA class-1 typing sera.
16. Kerman RH, Susskind B, Buelow R, Regan J, Pouletty P, Williams J, Gerolami K, Kerman DH, Katz SM, Van Buren CT, Kahan BD: Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection. Transplantation 1996, 62:201-205. Of the patients with IgG antibodies detected by PRA-STAT, 70% had rejections in the first year (P < 0.001) compared with 50% for patients with cytotoxic antibodies. Only 27% of patients with IgA antibodies had rejection.
17. Lim EC, Chia D, Gjertson DW, Koka P, Terasaki PI: In vitro studies to explain high renal allograft survival in IgA nephropathy patients. Transplantation 1993, 55:996-999.
18. Buelow R, Chiang TR, Monteiro F, Cornejo MC, Ellingson L, Claas F, Gaber O, Gelder F, Kotb M, Oresz C, Ponletty P: Soluble HLA antigens and ELISA: a new technology for crossmatch testing. Transplantation 1995, 60:1594-1599. A multicenter study found 99% concordance (854/864) for ELISA crossmatch compared with 78% for cytotoxicity.
19. Vaidya S, Rajaraman S, Orchard P, Fish JC: Frequency, immunoglobin subtype and clinical significance of antiphospholipid antibodies in ESRD patients [Abstract]. Hum Immunol 1996, 49(suppl 1):27. Antiphospholipid antibodies were detected in 11 out of 96 patients on dialysis. Non-lupus patients with antiphospholipid antibodies had a history of thrombic events.
20. Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA: Antiphospholipid antibodies (aPA) in patients with early nonfunctioning renal grafts [Abstract]. Hum Immunol 1996, 49(suppl 1):27. Antiphospholipid antibodies were detected in 11 out of 16 pretransplant sera from patients with nonfunctioning grafts.
21. Takemoto S, Terasaki PI, Cecka JM, Cho YW, Gjertson DW: Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. W Engl J Med 1992, 327:834-839.
22. Takemoto S, Terasaki PI, Gjertson DW, Cecka JM: Equitable allocation of HLA-compatible kidneys for local pools and for minorities. N Engl J Med 1994, 331:760-764.
23. Mosca F, Bertoni E, Tosi P, Bandini S, Rosati A, Pradella F, Mattiuz P, Taddei G, Nicita G, Rindi P, Rizzo G et al: Organ shortage and a long waiting list allow local kidney allocation to insure both short ischemia time and good HLA-A, B, DR matching. Transplant Proc 1995, 27:2695-2696. In a region with 342 waiting recipients 17% of kidneys were transplanted to recipients with 0 HLA B,DR mismatches, 45% to 1 B,DR mismatched recipients and the remaining kidneys to recipients with a maximum of 2 B,DR mismatches. They reported a low incidence of delayed graft function (22%) and 86% 1-year survival.
24. Farney AC, Matas AJ, Noreen HJ, Reinsmoen N, Segall M, Schmidt WJ, Gillingham K, Najarian JS, Sutherland DER: Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival? Clin Transplant 1996, 10:147-156. Cadaveric transplants re-exposed to mismatched HLA antigens had 70% 2-year survival compared with 61% for patients not exposed (P=0.41).
25. Cecka JM, Terasaki PI: Repeating HLA antigen mismatches in renal retransplants - a second class mistake? Transplantation 1994, 57:515-519.
26. Ichikawa Y, Hashimoto M, Hanafusa T, Kyo M, Fujimoto N, Matsuura O, Takahara S, Hayashi R, Ihara H, Ono Y et al: Delayed graft function does not influence long-term outcome in cadaver kidney transplants without mismatch for HLA-DRB1. Transplant Int 1995, 8:421-425. Non-heart beating donor kidney grafts had 88% 5-year survival for 44 DRB1 compatible kidneys, 69% for 83 DRB1 mismatched kidneys and 66% for 96 DR mismatched kidneys.
27. Connolly JK, Dyer PA, Martin S, Parrot NR, Pearson RC, Johnson RWG: Importance of minimizing HLA-DR mismatch and cold preservation time in cadaveric renal transplantation. Transplantation 1996, 61:709-714. Zero DR mismatched kidneys with ischemia less than 26 h had 89% 5-year survival compared with 75% for 1 DR mismatched kidneys (P=0.009).
28. Reviron D, Mercier P, Jaber K, Dussol B, Brunet P, Berland Y: Kidney transplantation: generic HLA DR compatibility reduces acute rejection episodes. Transplant Proc 1996, 28:2812-2813. Only 8% of transplants (2/26) had acute rejections for DR matched transplants defined using DR designations 1-18 compared with 21% for transplants with two broad DR matches.
29. Emonds MP, Mytilineos Y, Scherer S, Waer M, Vanrentergham Y, Opelz G, Dendievel J, Vermylen C: A single center evaluation of the Collaborative Transplant Study (CTS) DNA project. Transplant Int 1996, 9:468-475. A discrepancy rate of 7% was reported for DR antigens from 273 donor cells typed by cytotoxicity at a single center and validated by the Collaborative Transplant Study.
30. Terasaki PI, Gjertson DW, Cecka MJ, Takemoto S: Fit and match hypothesis for kidney transplantation. Transplantation 1996, 62:441-445. HLA antibodies, retransplantation, recipient race, recipient weight, ischemia damage, age of donor, mode of donor death, and dialysis after transplant affected the proportion of patients with low and high discharge serum creatinine but not graft outcome when stratified by creatinine level. Lack of rejection episodes and HLA mismatches were the only factors resulting in improved outcome in patients with elevated creatinine.
31. Terasaki PI, Koyama H, Cecka JM, Gjertson DW: The hyperfiltration hypothesis in human renal transplantation. Transplantation 1994, 57:1450-1454.
32. Gaston RS, Hudson SL, Julian BA, Laskow DA, Deierhoi MH, Sanders CE, Phillips MG, Diethelm AG, Curtis JJ: Impact of donor/recipient size matching on outcomes in renal transplantation. Transplantation 1996, 61:383-388. In this study transplants where the donor had a body surface area 20% smaller than the recipient were compared with those where the donor was 20% larger than the recipient. No difference was found in graft outcome but 75% of kidneys from large donors had serum creatinine < 1.8 mg/dl compared with 30% from small donors.
33. Miles AMV, Sumrani N, John S, Markell MS, Distant DA, Mansky V, Hong JH, Friedman EA, Sommer BG: The effect of kidney size on cadaveric renal allograft outcome. Transplantation 1996, 61:894-897. An analysis of 169 kidney transplant recipients comparing the ratio of kidney svolume to recipient body surface area did not reveal any significant differences in creatinine, proteinuria, or graft outcome 5 years after transplant.
34. Vereerstraeten P, Dupont E, Andrien M, de Pauw L, Abramowicz D, Goldman M, Kinnaert P: Influence of donor-recipient HLA-DR mismatches and OKT3 prophylactis on cadaver kidney graft survival. Transplantation 1995, 60:253-258. Recipients with beneficial DR mismatches had graft outcome similar to 0 DR mismatched recipients. Beneficial mismatches included donor or recipient DR5. Detrimental mismatches included donor DR1, donor or recipient DR2, or recipient DR6.
35. Doxiadis IIN, Smits JMA, Schreuder GMT, Persjin GG, van Houwelingen HC, Van Rood JJ, Claas FJH: Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996, 348:850-853. Patients with at least one of the seven 'taboo' mismatch combinations had 81% 1-year survival compared with 89% for patients with indifferent mismatches.
36. Takemoto S, Terasaki PI: Refinement of permissible HLA mismatches. In Clinical Transplants 1994. Edited by Cecka JM, Terasaki PI. Los Angeles: UCLA Tissue Typing Laboratory; 1995:451-466.
37. Laundy GJ, Bradley BA: The predictive value of epitope analysis in highly sensitized patients awaiting renal transplantation. Transplantation 1995, 59:1207-1213. A computer program was designed to calculate amino acid residue targets of patient HLA antisera. Potential donors were identified with antigens having amino acid residues in common with the recipient at the serum specificity positions, nonself naive epitopes that the patient never experienced, and nonself-tolerogens that the patient experienced, but became tolerant, anergic, or unresponsive. This analysis successfully predicted negative crossmatches for patients with 75-92% panel reactive antibody.
38. Takemoto S, Terasaki PI: HLA compatibility can be predicted by matching only three residues with outward oriented sidechains. Transplant Proc 1996, 28:1264-1266. Matching the polymorphic residues at positions 62, 65, and 163 resulted in a 3-year survival of 76% compared with 69% for transplants with mismatches.
39. Zantvoort FA, D'Amaro J, Persijn GG, Cohen B, Schreuder GMT, van Rood JJ, Thalogood J: The impact of HLA-A matching on long-term survival of renal allografts. Transplantation 1996, 61:841-844. In an evaluation including over 17 000 transplants between 1984 and 1991, relative risk of DR mismatches lost significance after 6 months, and B locus mismatches after 2 years. The relative risk of HLA-A locus mismatches reached significance after 3 years.